Tazemetostat hydrobromideProduct ingredient for Tazemetostat
- Name
- Tazemetostat hydrobromide
- Drug Entry
- Tazemetostat
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.6 Tazemetostat was first named in literature as EPZ-6438.5
Tazemetaostat was granted FDA approval on 23 January 2020.6
- Accession Number
- DBSALT002932
- Structure
Structure for Tazemetostat hydrobromide (DBSALT002932)
- Synonyms
- EPZ-6438 Monohydrobromide / Tazemetostat hydrobromide / Tazemetostat monohydrobromide
- External IDs
- EZ-438 / EZ438